Anti-obesity product safe in mid-stage study

	Tweet

Amylin Pharmaceuticals Inc said on Thursday a mid-stage study of its combination obesity product involving versions of hormones linked to appetite and metabolism yielded positive results.

The Phase 2, 28-week study randomized 608 overweight or obese patients to either placebo or various doses of the product, which contains the compounds pramlintide and metreleptin.

Patients with a body mass index of less than 35 treated with the highest dose experienced significantly more weight loss—11 percent on average compared with 1.8 percent for those on placebo.

The combination therapy had no suggestion of side effects involving the heart or brain—issues that have doomed other potential obesity treatments.

Amylin said the results confirm previous mid-stage results with the combination product and “provide a solid foundation for the company’s ongoing obesity development program.”

NEW YORK (Reuters)

RELATED STORIES:
Childhood Obesity Causes - Facts & Dangers   Heavy Passengers Weigh On Airlines’ Bottom Lines   Heavy breathing—an obscure link in asthma and obesity   New links among alcohol abuse, depression, obesity in young women found   Designer probiotics could reduce obesity   Genetic Factor Controls Health-Harming Inflammation in Obese   Obesity, passive smoking dangerous for unborn child   Bottle-fed babies may eat more, study hints   Big Belly and Obesity Linked to Increased Risk of Restless Legs Syndrome   Childhood Obesity Prevention from Pregnancy and Infancy Onward   Now an anti-binge nasal spray to tackle obesity   Could germs be making you fat?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]